CAPR / Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2022 Results Earnings Call Transcript

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong more_horizontal

The heavy selling pressure might have exhausted for Capricor (CAPR) as it is technically in oversold territory now. In addition to this technical meas more_horizontal

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformativ more_horizontal

Safety and Efficacy Results to be Presented at 2023 Parent Project Muscular Dystrophy Annual Conference Safety and Efficacy Results to be Presented at more_horizontal

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marba more_horizontal

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the s more_horizontal

Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda M more_horizontal

Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold more_horizontal